Testicular germ-cell neoplasms: curative approaches

Area of Science:

• Oncology
• Urology
• Surgical Oncology

Background:

• Testis cancer, primarily germ-cell tumors, often presents as low-volume disease.
• Early-stage (pathologic stage I) testis cancer has a nearly 100% cure rate, though relapse can occur.
• Relapsed cases are often salvageable with systemic chemotherapy.

Purpose of the Study:

• To review current management strategies for testis cancer.
• To discuss the efficacy and toxicity of various treatment modalities.
• To highlight the importance of careful follow-up in testis cancer patients.

Main Methods:

• Review of clinical presentation and treatment outcomes for testis cancer.
• Discussion of surgical techniques, including nerve-sparing retroperitoneal lymph node dissection.
• Analysis of chemotherapy regimens and their impact on cure rates and toxicity.

Main Results:

• Low-stage testis cancer (pathologic stage I) has a high cure rate, with relapses managed by chemotherapy.
• Nerve-sparing retroperitoneal lymph node dissection addresses infertility concerns associated with surgery.
• Stage II disease achieves high cure rates with either adjuvant or full-course chemotherapy.
• Advanced disease is primarily treated with systemic chemotherapy, with surgery as an adjunct for partial remission.

Conclusions:

• Testis cancer management involves a combination of surgery and chemotherapy tailored to disease stage.
• Minimizing chemotherapy toxicity while maintaining efficacy is a key focus.
• Prolonged follow-up is crucial, particularly for patients with teratoma in post-chemotherapy specimens, due to late recurrence risk.
• Accurate diagnosis and localization of primary testicular tumors are essential for effective treatment.